In this first prospective study to evaluate 92 proteins on the Olink Oncology II panel as early detection biomarkers for EC, HE4 and CA125 demonstrated the best discrimination between cases and controls in the EPIC and Janus cohorts for cancers diagnosed within a year and between 1 and 2 years of a diagnosis. Here, WFDC2 is linked to cancer.